Skip to main content
. 2011 Dec 12;6(12):e28887. doi: 10.1371/journal.pone.0028887

Figure 5. The ABAD inhibitor AG18051 prevents the toxicity and metabolic impairment caused by Aβ.

Figure 5

(A) Co-incubation of AG18051 and Aβ42 maintains the Aβ42-induced change in LDH levels at baseline levels. (B) The metabolic impairment as determined with the MTT assay is also prevented by co-incubation of Aβ42 with AG18051. (C) Pre-incubation of the cells with AG18051 for 24 hours prior to adding Aβ42 is similarly protective to Aβ's toxicity as measured with the MTT assay. *, P<0.05; **, P<0.01; ***, P<0.001.